NCT06189157 - MB-CART19.1 in Refractory SLE | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

SLE - Systemic Lupus Erythematosus

Interventions

BIOLOGICAL

MB-CART19.1

MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells

Trial Locations (3)

NOT_YET_RECRUITING

Universitätsklinikum Erlangen, Medizinische Klinik 3, Erlangen

RECRUITING

Otto-von-Guericke-Universität Magdeburg, Magdeburg

RECRUITING

Universitatsklinikum Tubingen - Medizinische Universitätsklinik Abt. II, Tübingen